Jacqualyn A Fouse Agios Pharmaceuticals, Inc. (AGIO) insider trading activity

Jacqualyn A Fouse is Director of AGIOS PHARMACEUTICALS, INC.. Currently has a direct ownership of 149,220 shares of AGIO, which is worth approximately $4.11 Million. The most recent transaction as insider was on Apr 10, 2025, when has been sold 7,497 shares (Common Stock) at a price of $25.9 per share, resulting in proceeds of $194,172. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 149K

5.99% 3M change

8.61% 12M change

Total Value Held $4.11 Million

JACQUALYN A FOUSE Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 10 2025	SELL Open market or private sale	$194,172 $25.9 p/Share	7,497 Reduced 4.78%	149,220 Common Stock
Apr 08 2025	BUY Exercise of conversion of derivative security	-	15,933 Added 9.23%	156,717 Common Stock
Jun 13 2024	BUY Exercise of conversion of derivative security	-	3,388 Added 2.35%	140,784 Common Stock
Apr 10 2024	SELL Open market or private sale	$214,642 $27.55 p/Share	7,791 Reduced 5.37%	137,396 Common Stock
Apr 08 2024	BUY Exercise of conversion of derivative security	-	15,934 Added 9.89%	145,187 Common Stock
Jan 24 2024	SELL Open market or private sale	$232,024 $21.64 p/Share	10,722 Reduced 7.66%	129,253 Common Stock
Jan 20 2024	BUY Exercise of conversion of derivative security	-	23,900 Added 14.58%	139,975 Common Stock
Jan 09 2024	SELL Open market or private sale	$192,909 $22.99 p/Share	8,391 Reduced 6.74%	116,075 Common Stock
Jan 05 2024	BUY Exercise of conversion of derivative security	-	17,500 Added 12.33%	124,466 Common Stock
Jun 30 2023	SELL Open market or private sale	$303,962 $28.36 p/Share	10,718 Reduced 9.11%	106,966 Common Stock
Jun 28 2023	BUY Exercise of conversion of derivative security	-	23,900 Added 16.88%	117,684 Common Stock
Apr 12 2023	SELL Payment of exercise price or tax liability	$101,006 $21.35 p/Share	4,731 Reduced 4.8%	93,784 Common Stock
Apr 08 2023	BUY Exercise of conversion of derivative security	-	15,933 Added 13.92%	98,515 Common Stock
Feb 16 2023	SELL Payment of exercise price or tax liability	$105,463 $28.91 p/Share	3,648 Reduced 4.23%	82,582 Common Stock
Feb 14 2023	BUY Exercise of conversion of derivative security	-	11,333 Added 11.62%	86,230 Common Stock
Feb 22 2022	SELL Payment of exercise price or tax liability	$106,840 $29.08 p/Share	3,674 Reduced 4.68%	74,897 Common Stock
Feb 18 2022	BUY Exercise of conversion of derivative security	-	12,379 Added 13.61%	78,571 Common Stock
Feb 14 2022	SELL Payment of exercise price or tax liability	$106,902 $30.5 p/Share	3,505 Reduced 5.03%	66,192 Common Stock
Feb 14 2022	BUY Exercise of conversion of derivative security	-	11,334 Added 13.99%	69,697 Common Stock
Feb 14 2021	SELL Payment of exercise price or tax liability	-	3,398 Reduced 5.5%	58,363 Common Stock
Feb 14 2021	BUY Exercise of conversion of derivative security	-	11,333 Added 15.5%	61,761 Common Stock

Also insider at

INCY

INCYTE CORP Healthcare

Director

MDGL

MADRIGAL PHARMACEUTICALS, INC. Healthcare

Director

JAF